[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588096":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":36,"responsibleParty":117,"collaborators":31,"id":119,"slug":31,"hasResults":120,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":31,"eligibilityCriteria":124,"healthyVolunteers":120,"sex":125,"minAge":126,"maxAge":31,"enrollmentInfo":127,"targetDuration":31,"studyType":130,"phases":131,"briefSummary":133,"conditions":134,"keywords":31,"overallStatus":39,"whyStopped":31,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":145},{"fullName":5,"class":6},"Ono Pharmaceutical Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ONO-4538","EXPERIMENTAL","ONO-4538 480 mg solution administered intravenously every 4 weeks",[13],"Drug: ONO-4538",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","every 4 weeks",[9],[20,21],"Nivolumab","Opdivo",[23],{"name":24,"affiliation":5,"role":25},"Project Leader","STUDY_DIRECTOR",[27,33],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"North America Clinical Trial Support Desk","CONTACT","+18665877745(Toll-Free)",null,"clinical_trial@ono-pharma.com",{"name":34,"role":29,"phone":35,"phoneExt":31,"email":32},"International Clinical Trial Support Desk","+17162141777(Standard)",[37,49,58,66,76,84,93,101,110,114],{"facility":38,"status":39,"city":40,"state":41,"zip":31,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":31},"Aichi Cancer Center","RECRUITING","Nagoya","Aichi-ken","Japan",{"type":44,"coordinates":45},"Point",[46,47],136.90641,35.18147,{"lat":47,"lon":46},{"facility":50,"status":39,"city":51,"state":51,"zip":52,"country":42,"cosmosGeoPoint":53,"geoPoint":57,"contacts":31},"Kyusyu University Hospital","Fukuoka","812-8582",{"type":44,"coordinates":54},[55,56],130.41667,33.6,{"lat":56,"lon":55},{"facility":59,"status":39,"city":60,"state":60,"zip":31,"country":42,"cosmosGeoPoint":61,"geoPoint":65,"contacts":31},"Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital","Hiroshima",{"type":44,"coordinates":62},[63,64],132.45,34.4,{"lat":64,"lon":63},{"facility":67,"status":39,"city":68,"state":69,"zip":70,"country":42,"cosmosGeoPoint":71,"geoPoint":75,"contacts":31},"Hokkaido University Hospital","Sapporo","Hokkaido","060-8648",{"type":44,"coordinates":72},[73,74],141.35,43.06667,{"lat":74,"lon":73},{"facility":77,"status":39,"city":78,"state":78,"zip":31,"country":42,"cosmosGeoPoint":79,"geoPoint":83,"contacts":31},"Kyoto University Hospital","Kyoto",{"type":44,"coordinates":80},[81,82],135.75385,35.02107,{"lat":82,"lon":81},{"facility":85,"status":39,"city":86,"state":87,"zip":31,"country":42,"cosmosGeoPoint":88,"geoPoint":92,"contacts":31},"Tohoku University Hospital","Sendai","Miyagi",{"type":44,"coordinates":89},[90,91],140.86667,38.26667,{"lat":91,"lon":90},{"facility":94,"status":39,"city":95,"state":95,"zip":31,"country":42,"cosmosGeoPoint":96,"geoPoint":100,"contacts":31},"Niigata University Medical & Dental Hospital","Niigata",{"type":44,"coordinates":97},[98,99],139.04125,37.92259,{"lat":99,"lon":98},{"facility":102,"status":39,"city":103,"state":104,"zip":31,"country":42,"cosmosGeoPoint":105,"geoPoint":109,"contacts":31},"Kindai University Hospital","Ōsaka-sayama","Osaka",{"type":44,"coordinates":106},[107,108],135.55069,34.49524,{"lat":108,"lon":107},{"facility":111,"status":39,"city":112,"state":113,"zip":31,"country":42,"cosmosGeoPoint":31,"geoPoint":31,"contacts":31},"Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital","Bunkyō-Ku","Tokyo",{"facility":115,"status":39,"city":116,"state":113,"zip":31,"country":42,"cosmosGeoPoint":31,"geoPoint":31,"contacts":31},"National Cancer Center Hospital","Chuo Ku",{"type":118,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100588096",false,"NCT06936943","ONO-4538 Study in Patients With Richter's Transformation","A Multicenter, Open-label, Uncontrolled Study to Evaluate the Efficacy and Safety of ONO-4538 in Patients With Richter's Transformation","Inclusion Criteria:\n\n* Histological diagnosis of diffuse large B-cell lymphoma (DLBCL)-type or Hodgkin lymphoma(HL)-type Richter's transformation with a history of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)\n* In the case of DLBCL-type Richter's transformation, refractory, intolerant or ineligible for treatment of DLBCL\n* Patients with measurable disease\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Expected to survive for 90 days or more\n\nExclusion Criteria:\n\n* Serious complications\n* Active multiple cancers\n* Active central nervous system (CNS) disease\n* History of allogeneic hematopoietic stem cell transplantation","ALL","18 Years",{"count":128,"type":129},14,"ESTIMATED","INTERVENTIONAL",[132],"PHASE2","Investigate the efficacy and safety of ONO-4538 in patients with Richter's transformation",[135],"Richter's Transformation","2026-02-12",{"date":138,"type":139},"2026-02-13","ACTUAL",{"date":141,"type":139},"2025-11-19",{"date":143,"type":129},"2030-07-31",{"name":5,"class":6},10]